Bangladexx - Ingliż - DGDA (Directorate General of Drug Administration)

euro pharma ltd. - dextrose anhydrous + fructose + potassium chloride + sodium bicarbonate + sodium chloride + sucrose - oral saline - 4.09 gm + 70 mg + 380 mg + 420 mg + 440 mg + 8.07 gm/250 ml

Bangladexx - Ingliż - DGDA (Directorate General of Drug Administration)

euro pharma ltd. - anhydrous glucose + potassium chloride + sodium chloride + trisodium citrate - oral saline - 6.75 gm + 750 mg + 1.3 gm + 1.45 gm

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

lantheus mi australia pty ltd - bicisate dihydrochloride -

Malta - Ingliż - Medicines Authority

pharmazac, s.a. 31 naousis str., 104 47, athens,, greece - sugammadex - solution for injection - sugammadex 200 mg - all other therapeutic products

Malta - Ingliż - Medicines Authority

pharmazac, s.a. 31 naousis str., 104 47, athens,, greece - sugammadex - solution for injection - sugammadex 500 mg - all other therapeutic products

Iżrael - Ingliż - Ministry of Health

medison pharma ltd - arsenic trioxide - solution for injection - arsenic trioxide 1 mg/ml - arsenic trioxide - arsenic trioxide - trisenox is indicated for induction of remission, and consolidation in adult patients with:• newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10 x 1000/μl) in combination with all-trans-retinoic acid (atra)• relapsed/refractory acute promyelocytic leukaemia (apl)(previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (pml/rar-alpha) gene.the response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

martindale pharmaceuticals ltd - clarithromycin - pdr/conc/soln for infus - 500 milligram(s) - macrolides; clarithromycin

Ingilterra - Ingliż - myHealthbox

rosemont pharmaceuticals ltd - risperidone - oral solution - 1mg/ml - other antipsychotics - it is indicated for the treatment of schizophrenia; for the treatment of moderate to severe manic episodes associated with bipolar disorders; for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer's dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others.; for the short-term symptomatic treatment (up to 6 weeks) of persistent aggression in conduct disorder in children from the age of 5 years and adolescents with subaverage intellectual functioning or mental retardation diagnosed according to dsm-iv criteria, in whom the severity of aggressive or other disruptive behaviours require pharmacologic treatment.

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

essential pharma ltd - carbamazepine - suppositories - 125 milligram - carbamazepine

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

essential pharma ltd - carbamazepine - suppositories - 250 milligram - carbamazepine